Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial
Biosimilar Liraglutide at a dose of up to 1.8 mg was non-inferior to reference Liraglutide and resulted in significant weight reduction and glycemic control (HbA1c, FPG and PPG) in Indian T2DM patients with obesity.
Authors
- Sanjay Choudhari (ORCID: https://orcid.org/0009-0005-5227-7671)
- Abhishek Mane
- Sanjay Kalra (ORCID: https://orcid.org/0000-0003-1308-121X)
- Sujoy Ghosh (ORCID: https://orcid.org/0000-0001-5397-961X)
- Saiprasad Patil (ORCID: https://orcid.org/0000-0002-4937-3188)
- Mayur Jadhav
- Bipin Sethi
- ManashP Baruah
- Anup Petare
- Hanmant Barkate
Institutions
- CARE Hospitals (IN)
- Apollo Hospitals (IN)
- Glenmark Pharmaceuticals (India) (IN)
- Bharti Hospital (IN)
- Manipal Hospital (IN)
Publication Details
- Journal
- Cardiovascular Diabetology – Endocrinology Reports
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1186/s40842-025-00219-7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00